Savings Opportunities With Upcoming Specialty and Traditional Generics

IPD Analytics has released a new report, “Savings Opportunities With Upcoming Specialty and Traditional Generics” examining key cost-saving opportunities tied to potential generic launches in 2026.

Generics and biosimilars generated $467 billion in savings in 2024, underscoring the value of proactive planning as more high-revenue brands approach loss of exclusivity (LOE). This analysis highlights drugs with significant 2024 U.S. gross sales, representing up to $33 billion in brand sales that may be at risk for generic savings. There is a significant trend in pulmonary arterial hypertension drugs losing exclusivity in 2026. Notably, generics may launch for Tyvaso, Adempas, Uptravi, and Opsumit.

The report also includes patent and regulatory outlooks, clinical considerations for utilization management, and implications for hospitals and health-systems.

Subscribers can access additional up-to-date information through the IPD Analytics platform, including the Projected Generic Launch Schedule and Unprotected Brands report generators.